Journal of Medical Economics · 2021 · 15 citations · 25 references
PharmacyPharmacoeconomicsPharmacotherapyCost-effectiveness AnalysisPharmacoeconomic ModelingRheumatologyComparative Effectiveness ModelingCost-effectiveness ComparisonCost-effectiveness ModelingHealthcare Cost AnalysisInflammatory Bowel DiseaseModel-based Economic EvaluationChronic Disease Cost AnalysisChronic Disease Cost ModelingClinical RemissionCost-effectivenessCost-effectiveness Of TherapyJanus Kinase Inhibitor TherapyTreatment Cost AnalysisTreatment Response Modeling
OBJECTIVES: Tofacitinib is an oral, small molecule Janus kinase (JAK) inhibitor for the treatment of ulcerative colitis (UC). This study assessed the cost-effectiveness of tofacitinib versus other available treatments for patients with moderate to severe UC following an inadequate response to conventional treatment and who are either naïve to or have failed previous biologics in Germany. METHODS: A Markov cohort model was developed to evaluate the differences in long-term costs and outcomes between tofacitinib and its comparators from the perspective of German statutory health insurance (SHI) for patients either naïve or exposed to biologics. Tofacitinib was compared to infliximab, infliximab biosimilar, adalimumab, adalimumab biosimilar, golimumab, vedolizumab, ustekinumab, and conventional therapy. Health states modeled were remission, treatment response, active UC, and post-colectomy. Patients not responding to treatment could switch to a different treatment. Treatment efficacy for induction and maintenance phases were assessed by a systematic literature review (SLR) and network meta-analysis (NMA). The model included costs associated with drug administration, adverse events, and medical resource use. Extensive deterministic and probabilistic sensitivity analyses (DSA and PSA) were conducted. RESULTS: Over a life-time horizon, patients treated with tofacitinib gained 0.035-0.083 quality-adjusted life-years (QALYs) and had direct cost savings to the SHI of €4,228-€17,184 compared to biologic treatments other than adalimumab biosimilar. When compared to adalimumab biosimilar, treatment with tofacitinib resulted in an incremental cost-effectiveness ratio (ICER) of €17,497 per QALY gained and can be considered a cost-effective alternative. Compared with conventional therapy, tofacitinib resulted in a lower ICER than all other biologics. The DSA showed that the model results were most influenced by differences in treatment efficacy. The PSA suggested confidence in the base-case results considering uncertainty around parameters. CONCLUSIONS: The results of this economic model suggest tofacitinib is a cost-effective treatment option for patients with moderate to severe UC in Germany.
25
null · Philosophy study · 2016 · 28.3K citations · Full text
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Paul Rutgeerts, William J. Sandborn, Brian G. Feagan et al. · New England Journal of Medicine · 2005 · 3.9K citations · Full text
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan, Paul Rutgeerts, Bruce E. Sands et al. · New England Journal of Medicine · 2013 · 2.9K citations · Full text
Epidemiology and Natural History of Inflammatory Bowel Diseases
Jacques Cosnes, Corinne Gower‐Rousseau, Philippe Seksik et al. · Gastroenterology · 2011 · 2.2K citations · Full text
Medicine, Immunology, Pathology +14
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn, Chinyu Su, Bruce E. Sands et al. · New England Journal of Medicine · 2017 · 1.7K citations · Full text